Treatment of oxidative stress disorders including contrast nephropathy, radiation damage and disruptions in the function of red cells
View Patent ↗Methods of treating or suppressing oxidative stress diseases and symptoms related to oxidative stress affecting normal electron flow in the cells or caused by reactive oxygen species with redox-active therapeutics. Use of redox-active therapeutics for the reduction, suppression or treatment of oxidative stress induced by chemical agents such as contrast agents and other nephrotoxic agents, by radiation exposure, and by disruptions in the transport of oxygen to tissues, is disclosed.
1. A method for reducing, preventing or treating radiation injury or radiation damage in a mammal exposed to ionizing radiation, said method comprising administering to the mammal a therapeutically effective amount of alpha-tocotrienol quinone, a stereoisomer, or a mixture of stereoisomers thereof.
2. The method according to claim 1 , wherein the alpha-tocotrienol quinone, or stereoisomer or mixture of stereoisomers thereof, is administered in combination with a pharmaceutically acceptable carrier.
3. The method according to claim 1 , where the ionizing radiation is selected from the group consisting of a diagnostic X-ray, radiation therapy in cancer treatment, a CAT-scan, a mammogram, a radionuclide scan, an interventional radiological procedure under computed tomography or fluoroscopy guidance, a tissue-incorporated radionuclide from ingestion of contaminated food or water, and uncontrolled exposure to ionizing radiation from a nuclear weapon, a radioactive spill, or cosmic radiation.
4. The method according to claim 1 , for preventing death of radiation-injured or radiation-damaged non-cancerous cells, comprising administering the alpha-tocotrienol quinone, or stereoisomer or mixture of stereoisomers thereof, to the mammal prior to an exposure to ionizing radiation.
5. The method according to claim 1 , for reducing an effect of radiation on normal cells in a mammal at risk for incurring exposure to radiation, comprising administering the alpha-tocotrienol quinone, or stereoisomer or mixture of stereoisomers thereof, to the mammal prior to an exposure to ionizing radiation.
6. The method according to claim 1 , for reducing an effect of radiation on normal cells in a mammal exposed to ionizing radiation, comprising administering the alpha-tocotrienol quinone, or stereoisomer or mixture of stereoisomers thereof, to the mammal subsequent to an accidental or intentional release of radioactive materials.
7. The method according to claim 1 , for protecting non-cancerous cells against radiation therapy, comprising administering the alpha-tocotrienol quinone, or stereoisomer or mixture of stereoisomers thereof, to the mammal prior to an exposure to radiation therapy.
8. The method according to claim 1 , where the method is a radiotherapy for treatment of cancer, comprising administering the alpha-tocotrienol quinone, or stereoisomer or mixture of stereoisomers thereof, to the mammal, and then administering to the mammal an effective amount of ionizing radiation, such that radiation injury to normal cells is decreased or eliminated.
9. The method according to claim 1 , wherein the mammal is exposed to whole body ionizing irradiation.
10. The method according to claim 1 , wherein the alpha-tocotrienol quinone, or stereoisomer or mixture of stereoisomers thereof, compound is administered systemically.
11. The method according to claim 1 , wherein the alpha-tocotrienol quinone, or stereoisomer or mixture of stereoisomers thereof, is administered by a route selected from the group consisting of oral, subcutaneous, transdermal, transmucosal, iontophoretic, intravenous, intraarterial, intramuscular, intraperitoneal, intranasal, subdural, spinal, epidural, rectal, gastrointestinal, and combinations thereof.
12. The method according to claim 1 , wherein the method comprises administering a therapeutically effective amount of alpha-tocotrienol quinone.
13. The method according to claim 12 , wherein the administering is oral.